Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers

Infection and Immunity

Volumn 70, Issue 7, 2002, Pages 3457-3467

  Hindle, Zoë ^a   Chatfield, Steven N ^a   Phillimore, Jo ^a   Bentley, Matthew ^a   Johnson, Julie ^a   Cosgrove, Catherine A ^a   Ghaem Maghami, Marian ^a   Sexton, Amy ^a   Khan, Mohammad ^a   Brennan, Frank R ^a   Everest, Paul ^a   Wu, Tao ^a   Pickard, Derek ^a   Holden, David W ^a   Dougan, Gordon ^a   Griffin, George E ^a   House, Deborah ^a   Santangelo, Joseph D ^a   Khan, Shahid A ^a   Shea, Jaqueline E ^a   Feldman, Robert G ^a   Lewis, David J M ^a   more..

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; SALMONELLA ENTERICA SEROVAR TYPHI ORAL LIVE VECTOR VACCINE ZH9; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM ORAL LIVE VECTOR VACCINE WT05; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; COLONY FORMING UNIT; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SALMONELLA; SALMONELLA ENTERICA; SEROTYPE; TYPHOID FEVER;

BACTERIAL PROTEINS; HEALTH STATUS; HUMAN EXPERIMENTATION; HUMANS; MEMBRANE PROTEINS; MUTAGENESIS; PHOSPHORUS-OXYGEN LYASES; SALMONELLA INFECTIONS; SALMONELLA TYPHI; SALMONELLA TYPHIMURIUM; TYPHOID FEVER; VACCINATION;

EID: 0036089517     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.7.3457-3467.2002     Document Type: Article

References (50)

1. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers
2. Salmonella maintains the integrity of its intracellular vacuole through the action of SifA
3. Macrophage-dependent induction of the Salmonella pathogenicity island 2 type III secretion system and its role in intracellular survival
4. Vaccination of chickens with chicken-derived Salmonella enteritidis phage type 4 aroA live oral Salmonella vaccines
5. Virulence and vaccine potential of Salmonella typhimurium mutants deficient in the expression of the RpoS (sigma S) regulon
6. Environmental regulation of Salmonella pathogenicity island 2 gene expression
7. Mutations in Salmonella pathogenicity island 2 (SPI2) genes affecting transcription of SPI1 genes and resistance to antimicrobial agents
8. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines: Effect of formulation on safety and immunogenicity
9. Safety and immunogenicity of phoP/phoQ -deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers
10. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector
11. Evaluation of Salmonella typhimurium mutants in a model of experimental gastroenteritis
12. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent
13. Alternative strategies for becoming an insider: Lessons from the bacterial world
14. Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells
15. Targeting of Salmonella typhimurium to vesicles containing lysosomal membrane glycoproteins bypasses compartments with mannose 6-phosphate receptors
16. Pathogenesis of salmonellosis: Studies of fluid secretion, mucosal invasion, and morphologic reaction in the rabbit ileum
17. Type III secretion of Salmonella enterica serovar typhimurium translocated effectors and SseFG
18. Genes encoding putative effector proteins of the type III secretion system of Salmonella pathogenicity island 2 are required for bacterial virulence and proliferation in macrophages
19. Trafficking of the salmonella vacuole in macrophages
20. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine
21. The shdA gene is restricted to serotypes of Salmonella enterica subspecies I and contributes to efficient and prolonged fecal shedding
22. Salmonella pathogenicity island 2-encoded proteins SseC and SseD are essential for virulence and are substrates of the type III secretion system
23. Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin
24. Typhoid fever vaccines
25. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors
26. Salmonella-triggered reactive arthritis
27. Salmonella: Immune responses and vaccines
28. HLA-B27 expression and reactive arthritis susceptibility in two patient cohorts infected with Salmonella typhimurium
29. Transcription of the SsrAB regulon is repressed by alkaline pH and is independent of PhoPQ and magnesium concentration
30. Intracellular bacteria as targets and carriers for vaccination
31. SseBCD proteins are secreted by the type III secretion system of Salmonella pathogenicity island 2 and function as a translocon
32. Characterization of aromatic- and purine-dependent Salmonella typhimurium: Attention, persistence, and ability to induce protective immunity in BALB/c mice
33. Identification of a pathogenicity island required for Salmonella survival in host cells
34. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18
35. The rpoS mutant allele of Salmonella typhi Ty2 is identical to that of the live typhoid vaccine Ty21a
36. Influence of the Salmonella typhimurium pathogenicity island 2 type III secretion system on bacterial growth in the mouse
37. Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium
38. Understanding mucosal responsiveness: Lessons from enteric bacterial pathogens
39. Aromatic-dependent "Salmonella sp." as live vaccine in mice and calves
40. Cholera vaccines
41. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers
42. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain
43. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
44. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers
45. Contribution of Salmonella typhimurium virulence factors to diarrheal disease in calves
46. A Salmonella virulence protein that inhibits cellular trafficking
47. Salmonella pathogenicity island 2-dependent evasion of the phagocyte NADPH oxidase
48. Molecular basis of Salmonella-induced enteritis